Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting
Go back to Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting| Actinium Pharmaceuticals, Inc. (NYSE: ATNM) | Delayed: 1.03 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.03 | 52 Week High | $3.50 | |||
| Open | $1.03 | 52 Week Low | $0.86 | |||
| Day High | $1.03 | P/E | N/A | |||
| Day Low | $1.03 | EPS | $-7.61 | |||
| Volume | 2,509 | |||||
